Editorials

193 Inflammatory Cell Markers as Indicators of Atherosclerotic Renovascular Disease
Stephen C. Textor and Lilach O. Lerman
See related article on page 224.

196 Racial and Ethnic Disparities in End Stage Renal Disease: Access Failure
Yoshio N. Hall
See related article on page 289.

Original Articles

Acute Kidney Injury / Acute Renal Failure
199 Association of AKI with Adverse Outcomes in Burned Military Casualties
Ian J. Stewart, Molly A. Tilley, Casey L. Cotant, James K. Aden, Christopher Gisler, Hana K. Kwan, Jeffrey McCorcle, Evan M. Renz, and Kevin K. Chung

Chronic Kidney Disease
207 Prolactin Levels, Endothelial Dysfunction, and the Risk of Cardiovascular Events and Mortality in Patients with CKD
Juan Jesús Carrero, John Kyriazis, Alper Sonmez, Ioannis Tzanakis, Abdul Rashid Qureshi, Peter Stenvinkel, Mutlu Saglam, Costas Stylianou, Halil Yaman, Abdullah Taslipinar, Abdulgaffar Vural, Mahmut Gök, Mujdat Yenicesu, Eugene Daphnis, and Mahmut Ilker Yilmaz

216 Ergocalciferol Supplementation in Children with CKD Delays the Onset of Secondary Hyperparathyroidism: A Randomized Trial
Rukshana Shroff, Mandy Wan, Ambrose Gullett, Sarah Ledermann, Rachel Shute, Craig Knott, David Wells, Helen Aitkenhead, Bahee Manickavasagar, William van’t Hoff, and Lesley Rees

Clinical Immunology and Pathology
224 Local and Systemic Cellular Immunity in Early Renal Artery Atherosclerosis
Carol Kotliar, Luis Juncos, Felipe Inserra, Elena M.V. de Cavanagh, Eduardo Chuluyan, Jorge B. Aquino, Alejandro Hita, Carlos Navari, and Ramiro Sánchez
See related editorial on page 193.

Clinical Nephrology
231 Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution
Samih H. Nasr, Anthony M. Valeri, Lynn D. Cornell, Mary E. Fidler, Sanjeev Sethi, Vivette D. D’Agati, and Nelson Leung

240 Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and Patrick H. Nachman

248 Soluble Klotho and Autosomal Dominant Polycystic Kidney Disease
Ivana Pavik, Philippe Jaeger, Lena Ebner, Diane Poster, Fabienne Krauer, Andreas D. Kistler, Katharina Rentsch, Gustav Andreisek, Carsten A. Wagner, Olivier Devuyst, Rudolf P. Wüthrich, Christoph Schmid, and Andreas L. Serra
258 Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation
Markus P. Schneider, Rolf Janka, Thomas Ziegler, Ulrike Raff, Martin Ritt, Christian Ott, Roland Veelken, Michael Uder, and Roland E. Schmieder

265 Causes of Alternative Pathway Dysregulation in Dense Deposit Disease

Epidemiology and Outcomes
275 The Risk for Medial Arterial Calcification in CKD
Nada Abou Hassan, Ellen T. D’Orsi, Carl J. D’Orsi, and W. Charles O’Neill

280 Obesity and Mortality Risk among Younger Dialysis Patients
Ellen K. Hoogeveen, Nynke Halbesma, Kenneth J. Rothman, Theo Stijnen, Sandra van Dijk, Friedo W. Dekker, Elisabeth W. Boeschoten, and Renée de Mutsert, for the Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) Study Group

289 Hispanic Ethnicity and Vascular Access Use in Patients Initiating Hemodialysis in the United States
Cristina M. Arce, Aya A. Mitani, Benjamin A. Goldstein, and Wolfgang C. Winkelmayer
See related editorial on page 196.

ESRD and Chronic Dialysis
297 A Randomized Controlled Trial Comparing Mupirocin and Polysporin Triple Ointments in Peritoneal Dialysis Patients: The MP³ Study
Rory F. McQuillan, Ernest Chiu, Sharon Nessim, Charmaine E. Lok, Janet M. Roscoe, Paul Tam, and Sarbjit Vanita Jassal

304 Relationship between CRP Polymorphism and Cardiovascular Events in Chinese Peritoneal Dialysis Patients
Peter Yam-Kau Poon, Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, and Philip Kam-Tao Li

310 Solar-Assisted Hemodialysis
John W. M. Agar, Anthony Perkins, and Alwie Tjipto

Hypertension
315 Association of Urinary Sodium/Potassium Ratio with Blood Pressure: Sex and Racial Differences
S. Susan Hedayati, Abu T. Minhajuddin, Adeeel Ijaz, Orson W. Moe, Essam F. Elsayed, Robert F. Reilly, and Chou-Long Huang

Mineral Metabolism/Bone Disease
323 Renal Phosphate Loss in Long-Term Kidney Transplantation
Supinda Sirilak, Kamonwan Chatsrisak, Atiporn Ingsathit, Surasak Kantachuvessiri, Vasant Sumethkul, Wasana Stitchantrakul, Piyanuch Radinahamed, and Sinee Disthabanchong

Renal Transplantation
332 Dialysis Modality and Outcomes in Kidney Transplant Recipients
Miklos Z. Molnar, Rajnish Mehrotra, Uyen Duong, Suphamai Bunnapradist, Lilia R. Lukowsky, Mahesh Krishnan, Csaba P. Kovessdy, and Kamyar Kalantar-Zadeh

Attending Rounds
342 Attending Rounds: Microangiopathic Hemolytic Anemia with Renal Insufficiency
William F. Clark and Ainslie Hildebrand

Commentary
348 The New FDA Labeling for ESA—Implications for Patients and Providers
Braden J. Manns and Marcello Tonelli

354 Erythropoietic Stimulating Agents and Quality of a Patient’s Life: Individualizing Anemia Treatment
Alan S. Kliger, Steven Fishbane, and Fredric O. Finkelstein
Mini-Review

358  Vitamin D Therapy in Chronic Kidney Disease and End Stage Renal Disease
    Michal L. Melamed and Ravi I. Thadhani

In-Depth Review

366  The Living Kidney Donor Evaluation: Focus on Renal Issues
    Ajay Kher and Didier A. Mandelbrot

On the Cover

What’s the diagnosis? Over the past decade, intravital multiphoton excitation fluorescence microscopy has provided stunning images and movies of the structure and function of the intact kidney with unparalleled spatial and temporal resolution. Because of its ability to directly visualize dynamic intrarenal processes in vivo without causing tissue damage, this noninvasive optical sectioning technique and imaging approach has revolutionized kidney research. This multiphoton image shows a glomerulus (lower right) in the living rat kidney that has been treated with puromycin aminonucleoside (PAN), a model of focal segmental glomerulosclerosis (FSGS). The red is albumin conjugated to Alexa594 to label the blood (plasma); green-yellow is Lucifer yellow, a freely filtered fluid marker labeling the glomerular filtrate. The nuclear dye Hoechst33342 was added to label cell nuclei (green). In this early phase of FSGS, small cysts in podocytes (unlabeled dark cells outside the glomerular capillary loops), and increased permeability of the glomerular filtration barrier (red-labeled albumin uptake in the early proximal tubule), are visible. Also, Lucifer yellow intensity in the tubular fluid nicely demonstrates the renal concentrating mechanism (intense fluorescence in the adjacent collecting duct versus the Bowman’s space and proximal tubule at the right). A corresponding video shows the filtration of Lucifer yellow injected into the carotid artery and the appearance of unlabeled podocytes (negative image). (Image and video, available online at www.cjasn.org, provided by Janos Peti-Peterdi and James Burford)